On 21 April 2020, FDA Circular No. 2020-015 was issued to provide interim measures to ensure access to vitamin drug products during the Coronavirus Disease 2019 (COVID-19) Pandemic. Subsequently, FDA Circular No. 2020-015-A was issued to extend the validity of said Circular.
Considering that there are regular updates on the quarantine status of different localities in the country, the validity of the provisions of this Circular should remain unaffected to ensure access to vitamin drug products during the COVID-19 pandemic.
Hence, FDA Circular No. 2020-015 shall be valid until 31 December 2020, regardless of the level of the imposed quarantine restriction, and subject to extension upon the review of this Office.
Attachment–>FDA-Circular-No.2020-015-B